My5-FU+ measures levels of an anti-cancer drug such as 5-fluorouracil (5-FU) in the blood of cancer patients.
In poland, Genoxa will provide My5-FU testing services to oncologists, thus facilitating them to individualize the dose of 5-FU to optimize therapeutic efficacy and reduce toxicity for their patients.
As per the agreement, AB Analitica will distribute My5-FU testing kits to hospital and reference laboratories.
Genoxa co-founder and CEO Artur Wilandt said they are pleased to launch the My5-FU testing kits to the Polish oncology community and provide cancer patients better treatment options.
